(AOF) – Novavax is expected to fall in pre-market on Wall Street after announcing that European Union regulators have postponed their decision on whether or not to approve its Covid-19 vaccine adapted to the XBB variant: the European Agency Medicines Agency (EMA) has asked Novavax for more information on the vaccine. “As part of the ongoing review process, the EMA’s Committee for Medicinal Products for Human Use (CHMP) has asked additional questions which we are responding to promptly,” Novavax said in a statement emailed to Reuters.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
